IMPORTANCE Rotavirus infection is the global leading cause of diarrhea-associated morbidity and mortality among children younger than 5 years.
D iarrheal disease was the fourth leading cause of death among children younger than 5 years in 2015, responsible for nearly 500 000 deaths. 1,2 Furthermore, rotavirus infection was responsible for 29.3% (95% uncertainty interval [UI] , 24.6%-35.9%) of all diarrheal deaths among children younger than 5 years in 2015 (146 500 deaths; 95% UI, 118 000-183 500). 2 Diarrhea-associated mortality has decreased since 1990 by nearly 65% in part because of improvements in safe water and sanitation and reductions in undernutrition among children younger than 5 years. 2 Sustained efforts to scale and implement effective interventions must remain the long-term goal to alleviate the global diarrhea burden. In response to the urgent need to prevent avertable diarrhea episodes and their associated mortality, the World Health Organization (WHO) recommended that rotavirus vaccines be included in immunization programs in the European region and the Americas in 2006, a recommendation that was extended to all regions worldwide in 2009. 3 In addition, Gavi, the Vaccine Alliance actively supports rotavirus vaccination by subsidizing the cost of vaccination in eligible countries. 3 Rotavirus is 1 of the 13 diarrheal etiologic agents measured in the Global Burden of Disease Study 2016 (GBD 2016) . 1, 4, 5 The GBD 2016 is a systematic, scientific effort to produce comparable estimates of disease burden, including rotavirus diarrhea, for each age, sex, geographic location, and year from 1990 through 2016. This study describes the incidence and mortality of rotavirus infection among children younger than 5 years and reveals the urgent need for interventions to reduce diarrhea risk, treat severe diarrhea episodes, and prevent rotavirus diarrhea.
Methods
Detailed methods on the GBD and diarrhea estimation in the GBD have been previously published. 1, 4, 5 This report describes these methods briefly, focusing on etiologic attribution and changes from previous GBD methods. Intermediate models, input data, and code are available on the Global Health Data Exchange website. 6 Institutional review board approval for the GBD 2016 was granted by the University of Washington.
Diarrhea-associated mortality was modeled in the Cause of Death Ensemble model (CODEm) platform. CODEm is a Bayesian, hierarchical, space-time, ensemble model tool. 2, 7 CODEm produces a wide variety of submodels designed to include a diverse set of covariates and model types. eTable 1 in the Supplement provides a complete list of the covariates used. Each submodel is weighted based on out-of-sample predictive validity and contributes draws to a final set of 1000 draws. These predictive regression models produce estimates of cause-specific mortality for each age, sex, geographic location, and year based on vital registration, verbal autopsy, and surveillance system data.
Diarrhea incidence was modeled in DisMod-MR, version 2.1 (DisMod). DisMod is a Bayesian, hierarchical metaregression tool. 5 Like CODEm, DisMod uses space-time information and covariates to produce modeled estimates for each age, year, geographic location, and sex. DisMod also contains a compartmental model that enforces consistency among incidence, prevalence, and mortality. Input data are from the scientific literature, population-representative surveys, and health care use records.
Rotavirus was attributed to diarrhea-associated mortality and morbidity using a counterfactual approach called a population attributable fraction (PAF) . 1 This study's approach accounted for pathogen codetection and detection in healthy individuals and does not necessitate a 1-pathogen-to-1-episode association. Detection of rotavirus was based on a molecular diagnostic case definition. 8 The PAF is defined as follows 9 : PAF = Proportion × (1 − 1/OR) where OR is the odds ratio of diarrhea given pathogen detection and proportion is the modeled frequency of detection of rotavirus in diarrhea samples. The ORs are based on results from the Global Enteric Multicenter Study (GEMS) (eTable 2 in the Supplement). 8, 10 The proportion estimates are from Dis-Mod models in which the input data are from scientific literature and modeled for each age, sex, year, and geographic location. Input data are given in eTable 3 and eFigure 1 in the Supplement. Results were adjusted to match a molecular diagnostic case definition using the sensitivity and specificity of enzyme-linked immunosorbent assay (ELISA) compared with the molecular diagnostic definition.
This study uses a systematic reanalysis of the GEMS samples using quantitative polymerase chain reaction (PCR). 8 The modeling strategy requires that the continuous quantitative PCR test results are dichotomized into positive and negative results so that the ORs represent the strength of association between rotavirus and diarrhea. 11 To do this, we identified the lowest cycle threshold in which the diagnostic accuracy was maximized (eFigure 2 in the Supplement). A summary of the input data for these models is provided in eTable 3 and eFigure 1 in the Supplement. To attribute diarrhea episodes and deaths due to rotavirus infection, the PAF estimates were multiplied by the diarrhea episode and death estimates. All estimates in the GBD 2016 are produced at the draw level with uncertainty carried through each step of the process, and values presented in this study are the mean values from these distributions, with UIs represented by the 2.5th and 97.5th percentiles of the distribution.
The ramifications of the rotavirus vaccine were evaluated using an analysis of the modeled rotavirus vaccine coverage. Rotavirus vaccine coverage was modeled using a spacetime gaussian process regression in which the input data were the ratio of rotavirus vaccine coverage estimates from surveys and implementation programs to the coverage of 3 doses of diphtheria and tetanus toxoids and pertussis (DTP3) vaccine. 12 Rotavirus vaccine coverage was modeled as a ratio to DTP3 coverage because it was assumed that DTP3 coverage was the upper bound of a routine immunization program's ability to deliver the vaccine (eFigure 3 in the Supplement). A metaanalysis of the vaccine efficacy for severe diarrhea based on the reported values in a 2016 systematic review 13 was used to estimate the relative reduction in rotavirus diarrhea associated with rotavirus vaccine use. The vaccine efficacy and the modeled vaccine coverage were used to estimate a counterfactual estimate of the rotavirus PAF in the absence of the vaccine by sex, year, and geographic location. The difference between the observed and a counterfactual estimate of the expected rotavirus PAF based on the vaccine coverage and efficacy was used to determine the reduction in deaths from diarrhea attributable to the vaccine.
Results
Rotavirus infection was responsible for an estimated 128 500 deaths (95% UI, 104 500-155 600) among children younger than 5 years in 2016; thus, 28.8% (95% UI, 25.0%-32.6%) of the deaths from diarrhea in this age group were attributable to ro- tavirus (Table) . The rotavirus-associated mortality rate was highest in sub-Saharan Africa, Southeast Asia, and South Asia (Figure 1) . A total of 104 733 deaths from rotavirus infection (95% UI, 83 406-128 842) among those younger than 5 years occurred in sub-Saharan Africa. Thirty percent of diarrhea deaths among children younger than 5 years were attributable to rotavirus infection in many geographic locations, seemingly independent of space or sociodemographic index ( Figure 2 and Figure 3) , with the attributable fraction caused by rotavirus ranging from 4.6% (95% UI, 3.0%-6.5%) in Nicaragua to 64.2% (95% UI, 61.0%-67.6%) in the Democratic Republic of the Congo (Figure 2 and eTable 4 in the Supplement). More than 50% of deaths from diarrhea in highincome countries, such as Denmark (51.0%; 95% UI, 44.8%-57.0%) and Finland (62.6%; 95% UI, 52.2%-73.0%), were attributable to rotavirus infection, indicating that it is a ubiquitous infection among children younger than 5 years. Rotavirus infection was responsible for more than 258 million episodes of diarrhea among children younger than 5 years in 2016 (95% UI, 193 million to 341 million), an incidence of 0.42 cases per child-year (95% UI, 0.30-0.53) (Table and eTable 4intheSupplement). The incidence among children younger than 5 years ranged from 0.024 cases per child-year (95% UI, 0.015-0.038) in South Korea to 1.63 cases per child-year (95% UI, 1.29-2.01) in the Democratic Republic of the Congo (Table and eTable 4 in the Supplement). Rotavirus was also an important cause of diarrhea morbidity in high-income locations, such as the United States, accounting for 593 000 episodes among children younger than 5 years (95% UI, 375 000-875 300) (country-level results are provided in eTable 4 in the Supplement). The estimated incidence of severe rotavirus diarrhea was 29.4 per 1000 child-years (95% UI, 22.2-38.0), accounting for 18 882 800 severe cases (95% UI, 14 263 600-24 446 700). Rotavirus infection was responsible for an estimated 1 537 000 (95% UI, 285 000-7 750 500) hospitalizations globally among children younger than 5 years in 2016. In addition, rotavirus-associated mortality among children younger than 5 years decreased by 48.2% (95% UI, 37.3-57.0) between 1990 and 2016 ( Figure 3B) .
The introduction and expanded use of the rotavirus vaccine have already contributed to changes in rotavirus burden. This study estimated that 27.8% of children younger than 5 years were vaccinated against rotavirus in 2016 (eFigure 3 in the Supplement). The rotavirus vaccine averted an estimated 28 800 (95% UI, 14 600-46 700) deaths in 2016, including 24 200 (95% UI, 12 300-38 700) in sub-Saharan Africa, 1620 (95% UI, 870-2600) in Latin America, and 1410 (95% UI, 850-2300) in Southeast Asia, East Asia, and Oceania ( Figure 4) . The number of deaths averted depends on the fraction attributable to rotavirus infection and the vaccine effectiveness. This study estimated that full use of the rotavirus vaccine could have averted an additional 83 200 deaths (95% UI, 37 000-168 000) in 2016 (eTable 5 in the Supple- 
Discussion

Rotavirus Burden
Although the burden of rotavirus has decreased during the past decade, rotavirus continues to be the leading cause of diarrhea-associated mortality among children younger than 5 years, responsible for nearly 130 000 deaths annually.
Rotavirus was the third leading pathogen associated with mortality among those younger than 5 years in 2016, behind malaria (517 000 deaths) and Streptococcus pneumoniae (359 000 deaths). 4 On average, more than 40% of children younger than 5 years had an episode of rotavirus diarrhea in 2016. However, there is a large discrepancy between the incidence and mortality of rotavirus infection in high-and low-income locations.
The number of deaths from diarrhea among children younger than 5 years has decreased by more than 45% since 2005. 4 The changing mortality of rotavirus infection mirrors the large global decreases in diarrhea-associated mortality that have previously been attributed to improvements in water and sanitation and reductions in childhood undernutrition. How- ever, rotavirus was estimated to be responsible for 7% of diarrhea episodes in those younger than 5 years in the United States and 10% in Canada, suggesting that rotavirus may be transmitted in pathways other than the fecal-oral route. 15 The high transmissibility of rotavirus and difficulty in controlling it make widespread vaccine coverage a priority.
Rotavirus Vaccine and Diarrheal Disease Burden
By the end of 2015, Gavi, the Vaccine Alliance had funded rotavirus vaccine introductions in 37 countries and the Democratic Republic of the Congo, Bangladesh, and Nigeria, with introduction in Pakistan and India being planned in the near future, 16 whereas 92 countries overall have introduced the vaccine. 17 Recently developed vaccines, manufactured in India 18 or China, 19 will also likely contribute to more widespread use of rotavirus vaccine in these countries. Reductions in child deaths and hospitalizations from rotavirus diarrhea are expected after these introductions. Several countries that have implemented routine childhood vaccination against rotavirus have documented fewer cases of severe diarrhea and rotavirus disease requiring hospitalization 20 and decreases of 22% to 50% in diarrhea-associated mortality. 21, 22 The present study showed that the vaccine has already alleviated the burden of diarrhea among those younger than 5 years in several countries that have introduced the vaccine, including Finland, Rwanda, and Ghana (eTable 5 and eFigure 4 in the Supplement). This study will provide decision makers with valuable information to develop strategies and achieve the international targets for alleviating the substantial burden of diarrheal diseases.
Comparison With Other Estimates
The GBD is on an annual publication cycle in which the number of deaths due to rotavirus diarrhea and deaths due to all causes is reestimated every year, allowing for incremental improvements to the rotavirus burden estimation strategy. A comparison of estimates between GBD 2015 and 2016 is shown in eFigure 5 in the Supplement. The number of deaths from rotavirus infection among children younger than 5 years is similar between GBD 2016 (128 500; 95% UI, 104 500-155 600) and GBD 2015 (146 000; 95% UI, 118 000-183 000). 1,4 A recent publication 23 made comprehensive comparisons between the GBD 2013 estimates for rotavirusassociated mortality and those produced by the Child Health Epidemiology Research Group (CHERG), the WHO, and the Centers for Disease Control and Prevention (CDC). The number of deaths from rotavirus infection in the GBD 2016 is lower than the estimates produced by the other groups. The WHO and CDC estimated 215 757 deaths in 2013, and CHERG esti-mated 157 398 in 2013. [23] [24] [25] In contrast, the GBD 2016 estimated 193 300 deaths in 2010 (95% UI, 163 800-227 500) and 128 500 deaths (95% UI, 104 500-155 600) in 2016. Each set of estimates used different approaches, input data, and model assumptions to reach their conclusions. The CHERG as well as WHO and CDC groups used the same estimate of diarrheaassociated mortality among those younger than 5 years, which is marginally larger than that produced by the GBD. 23
Limitations
Data on the incidence of diarrhea and its causes are scarce-an issue that is often most prevalent in high-burden locations. Subsequently, estimates in these locations rely more heavily on models based on predictive validity. To address this issue of sparse mortality and etiologic data, we propagated uncertainty through every step of the modeling process (eFigure 6 in the Supplement). In addition, this study addressed the association among the rotavirus vaccine, hospitalizations, and burden but is limited by the fact that hospitalization in many countries is not a function of severity but of access to care. 26 In regions such as these, when hospital access is not restricted, hospitalization rates are much higher. There may be a shift in the use of diagnostics for rotavirus from ELISA to molecular diagnostics, particularly for surveillance and clinical trials. [27] [28] [29] Although the sensitivity and specificity of ELISA diagnostics to molecular diagnostic detection frequency are high (>95%), there may be a detection bias among studies included in this analysis, particularly if there are strong time or geographic trends in the types of diagnostics used. The use of molecular diagnostics as a criterion standard and the association between ELISA and quantitative PCR used in the present study was informed by a single case-control study (GEMS). 8, 10 In addition, because GEMS was a study of moderate to severe diarrhea, this study makes the assumption that the cause of severe diarrhea is comparable with that of fatal diarrhea.
Conclusions
These results suggest that rotavirus is still a highly prevalent cause of diarrhea worldwide and is responsible for a substantial nonfatal burden of diarrhea globally. These findings call for renewed efforts to prevent rotavirus infection through increased efforts to improve vaccination coverage, water and sanitation, and access to and quality of medical care. Governments, donors, and health care professionals should use these findings to reduce the burden of rotavirus at the country, regional, and global levels.
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Level is ranked from 1 (causally related) to 3 (distally related). Direction is the required negative or positive association with diarrhea mortality. The odds ratios of diarrhea given the presence of rotavirus in a stool sample, based on a molecular diagnostic case definition, is shown for the two age groups used in this study.
Covariate Level Direction
Age
Odds ratio (95% CI) Under 1 15.4 (9.9-23.1) Over 1 14.1 (7.4-25.7) eTable 3. Data points used for rotavirus proportion modeling by country and source population. 202,885 (121,429-317,854) Southeast Asia 3,765 (2,895-4,789) 6.6 (5.1-8.4) 507.9 (360.5-706.1) 29,845,328 (21,186,178-41,494,613) Cambodia 96 (55-158) 5.1 (2.9-8.4) 667.9 (453.8-921.4) 1,223,928 (831,622-1,688,584) Indonesia 1,994 (1,498-2,611) 8.8 (6.6-11.5) 538.7 (369.3-776.0) 12,948,711 (8,878,371-18,654,115) (107.9-262.5)   1,899,833  (1,187,968-2,890,610 
